Apogee Therapeutics, Inc. (APGE)

53,38 +0,47 (+0,88%) Ab 02:40PM EDT. Markt geöffnet.

Apogee Therapeutics, Inc.

221 Crescent Street
Building 17 Suite 102b
Waltham, MA 02453
United States
650-394-5230
https://www.apogeetherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 91

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Michael Thomas Henderson M.D.	CEO & Director	1,17M	N/A	1990
Ms. Jane Pritchett V. Henderson	Chief Financial Officer	843,64k	N/A	1966
Dr. Carl Linden Dambkowski M.D.	Chief Medical Officer	870,83k	N/A	1986
Ms. Noel Kurdi	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Matthew Batters J.D.	Chief Legal Officer & Corporate Secretary	N/A	N/A	1976
Ms. Emily Cox	VP & Head of People	N/A	N/A	N/A
Dr. Rebecca Dabora Ph.D.	Chief Development Officer	N/A	N/A	1960
Ms. Wendy Aspden-Curran	Senior Vice President of Clinical Operations	N/A	N/A	N/A
Dr. Drew Badger Ph.D.	Senior VP and Head of Regulatory Affairs & Toxicology	N/A	N/A	N/A
Ms. Monica Forbes	Senior Vice President of Finance	N/A	N/A	1976

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Apogee Therapeutics, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.